Generic medications in ophthalmology

Matt Zore, Alon Harris, Leslie Abrams Tobe, Brent Siesky, Ingrida Januleviciene, Jennifer Behzadi, Annahita Amireskandari, Patrick Egan, Kevin Garff, Barbara Wirostko

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The purpose of this review is to discuss the process of genericisation of medications in the US and Europe with a focus on ophthalmic drugs. Regulatory guidelines of the US Food and Drug Administration and the European Medicines Agency will be discussed, and the advantages and concerns of genericisation will be explored. We will look at various studies concerning the safety and efficacy of generic drugs compared to their branded counterparts. In particular, the challenges of assuring bioequivalence and therapeutic equivalence in topical ophthalmic drugs will be examined.

Original languageEnglish
Pages (from-to)253-257
Number of pages5
JournalBritish Journal of Ophthalmology
Volume97
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

Ophthalmology
Generic Drugs
Therapeutic Equivalency
United States Food and Drug Administration
Pharmaceutical Preparations
Guidelines
Safety
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Zore, M., Harris, A., Tobe, L. A., Siesky, B., Januleviciene, I., Behzadi, J., ... Wirostko, B. (2013). Generic medications in ophthalmology. British Journal of Ophthalmology, 97(3), 253-257. https://doi.org/10.1136/bjophthalmol-2012-302245

Generic medications in ophthalmology. / Zore, Matt; Harris, Alon; Tobe, Leslie Abrams; Siesky, Brent; Januleviciene, Ingrida; Behzadi, Jennifer; Amireskandari, Annahita; Egan, Patrick; Garff, Kevin; Wirostko, Barbara.

In: British Journal of Ophthalmology, Vol. 97, No. 3, 03.2013, p. 253-257.

Research output: Contribution to journalArticle

Zore, M, Harris, A, Tobe, LA, Siesky, B, Januleviciene, I, Behzadi, J, Amireskandari, A, Egan, P, Garff, K & Wirostko, B 2013, 'Generic medications in ophthalmology', British Journal of Ophthalmology, vol. 97, no. 3, pp. 253-257. https://doi.org/10.1136/bjophthalmol-2012-302245
Zore, Matt ; Harris, Alon ; Tobe, Leslie Abrams ; Siesky, Brent ; Januleviciene, Ingrida ; Behzadi, Jennifer ; Amireskandari, Annahita ; Egan, Patrick ; Garff, Kevin ; Wirostko, Barbara. / Generic medications in ophthalmology. In: British Journal of Ophthalmology. 2013 ; Vol. 97, No. 3. pp. 253-257.
@article{eec77d7e34d14a33a4a6f3232a19441e,
title = "Generic medications in ophthalmology",
abstract = "The purpose of this review is to discuss the process of genericisation of medications in the US and Europe with a focus on ophthalmic drugs. Regulatory guidelines of the US Food and Drug Administration and the European Medicines Agency will be discussed, and the advantages and concerns of genericisation will be explored. We will look at various studies concerning the safety and efficacy of generic drugs compared to their branded counterparts. In particular, the challenges of assuring bioequivalence and therapeutic equivalence in topical ophthalmic drugs will be examined.",
author = "Matt Zore and Alon Harris and Tobe, {Leslie Abrams} and Brent Siesky and Ingrida Januleviciene and Jennifer Behzadi and Annahita Amireskandari and Patrick Egan and Kevin Garff and Barbara Wirostko",
year = "2013",
month = "3",
doi = "10.1136/bjophthalmol-2012-302245",
language = "English",
volume = "97",
pages = "253--257",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "3",

}

TY - JOUR

T1 - Generic medications in ophthalmology

AU - Zore, Matt

AU - Harris, Alon

AU - Tobe, Leslie Abrams

AU - Siesky, Brent

AU - Januleviciene, Ingrida

AU - Behzadi, Jennifer

AU - Amireskandari, Annahita

AU - Egan, Patrick

AU - Garff, Kevin

AU - Wirostko, Barbara

PY - 2013/3

Y1 - 2013/3

N2 - The purpose of this review is to discuss the process of genericisation of medications in the US and Europe with a focus on ophthalmic drugs. Regulatory guidelines of the US Food and Drug Administration and the European Medicines Agency will be discussed, and the advantages and concerns of genericisation will be explored. We will look at various studies concerning the safety and efficacy of generic drugs compared to their branded counterparts. In particular, the challenges of assuring bioequivalence and therapeutic equivalence in topical ophthalmic drugs will be examined.

AB - The purpose of this review is to discuss the process of genericisation of medications in the US and Europe with a focus on ophthalmic drugs. Regulatory guidelines of the US Food and Drug Administration and the European Medicines Agency will be discussed, and the advantages and concerns of genericisation will be explored. We will look at various studies concerning the safety and efficacy of generic drugs compared to their branded counterparts. In particular, the challenges of assuring bioequivalence and therapeutic equivalence in topical ophthalmic drugs will be examined.

UR - http://www.scopus.com/inward/record.url?scp=84874662695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874662695&partnerID=8YFLogxK

U2 - 10.1136/bjophthalmol-2012-302245

DO - 10.1136/bjophthalmol-2012-302245

M3 - Article

C2 - 23143788

AN - SCOPUS:84874662695

VL - 97

SP - 253

EP - 257

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 3

ER -